Adult Dosing

Osteoarthritis

• 1500 mg PO bid; alt: 3000 mg PO qhs
• 750 mg PO tid in geriatrics

Rheumatoid arthritis

• 1500 mg PO bid; alt: 3000 mg PO qhs
• 750 mg PO tid in geriatrics

Mild-moderate pain

• 1500 mg PO bid
• 2000-3000 mg/day PO div bid-tid in geriatrics

Fever

• 2000-3000 mg/day PO div bid-tid

Pediatric Dosing

Juvenile idiopathic arthritis

• 12-37 kg: 50 mg/kg/day PO div bid
• >37 kg: 2250 mg/day PO div bid-tid

Mild-moderate pain

• 12-37 kg: 50 mg/kg/day PO div bid
• >37 kg: 2250 mg/day PO div bid-tid

Inflammation

• 12-37 kg: 50 mg/kg/day PO div bid
• >37 kg: 2250 mg/day PO div bid-tid

[Outline]

• Adult Dosing
• Pediatric Dosing

• Relief of mild to moderate pain
• Treatment of rheumatic fever
• Treatment of rheumatoid arthritis including juvenile arthritis and osteoarthritis
• Management of fever

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to non-acetylated salicylates
• GI bleeding
• Advanced chronic renal insufficiency
• Flu-like symptoms or chickenpox
• Influenza

• N/A

Renal Dose Adjustment

• Advanced chronic renal insufficiency: Contraindicated

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined; use with caution

• Rare occasions of serious Reye's Syndrome may occur in children and teenagers having chicken pox, influenza, or flu symptoms. This drug is not recommended for use in children and teenagers with chicken pox, influenza or flu symptoms
• Increased risk of adverse GI events, including stomach bleeding may occur with concomitant use of alcohol
• Cross reactivity, including bronchospasm, is associated with use of this drug
• Concomitant use of other salicylate-containing products and choline magnesium trisalicylate may lead to increase in plasma salicylate concentration and result in potentially toxic salicylate levels
• Periodically assess plasma salicylate levels during therapy with this drug
• Monitor pain relief and temperature after administration of this drug. On development of tinnitus, flushing, tachycardia, hyperventilation, sweating or thirst, withhold this drug

Cautions: Use cautiously in

• Renal impairment
• Hepatic impairment
• Cardiovascular disease
• Risk of cardiac disease
• Hypertension
• CHF
• GI bleed
• History of peptic ulcer disease
• Fluid retention
• Dehydration
• Coagulation disorder
• Use of anticoagulant
• Use of corticosteroid
• Concurrent use with diuretics
• Use of ACEI or ARB
• Use of alcohol
• Smokers
• Asthma
• Prolonged use
• Elderly
• Debilitated patients

Pregnancy Category:C

Breastfeeding: Safety unknown; Potential for significant salicylate absorption by the nursing infant exists; exercise caution when this drug is administered to a nursing woman.

• CV: Myocardial infarction, hypertension
• EENT: Hearing loss
• CNS: Stroke
• GU: Renal papillary, necrosis, nephrotoxicity
• GI: Hepatotoxicity, hepatitis, GI bleed, GI ulceration, GI perforation, nausea, vomiting, dyspepsia, indigestion, diarrhea, constipation
• RESP: Bronchospasm
• HEMA: Prolonged bleeding time
• MISC: Reye's syndrome

• Salicylate; precise mechanism of action unknown; relieves pain by inhibiting synthesis and release of prostaglandins; reduces fever by vasodilation of peripheral vessels
• Rapid absorbtion
• Primarily metabolized by liver; CYP450: Unknown
• Excreted in urine
• Half-life: 9-17 hrs

US Trade Name(s)

• Only generic available

US Availability

choline magnesium trisalicylate (generic)

• TABS: 500, 750, 1000 mg
• LIQ: 500 mg/5 mL

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Analgesics

Salicylates

Rheumatologic

Salicylates